Open-label study to assess efficacy (diagnostic performance) and safety of a single dose (i.v.) of NMK36 in patients with clinically- suspected glioma
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Glioma
- Focus Adverse reactions; Diagnostic use
- Sponsors Nihon Medi-Physics
- 17 Mar 2017 Status changed from active, no longer recruiting to completed.
- 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2016 New trial record